United States News All stories

Kymera Therapeutics (NASDAQ:KYMR) reported positive findings from its Phase 1 clinical trial evaluating KT-621, a first-in-class oral small molecule STAT6 degrader, in healthy Japanese adults.

Rocket Pharmaceuticals (NASDAQ:RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), generating $180 million in gross, non-dilutive cash proceeds.

United Community Banks (NYSE:UCB) entered into a definitive agreement to sell its specialty equipment finance business, comprising Navitas Credit Corp. and NLFC Reinsurance Corp., to investment funds managed by private equity firm Wafra.

Medallion Bank (NASDAQ:MBNKO), a wholly owned subsidiary of Medallion Financial Corp. (NASDAQ:MFIN), announced an orderly leadership succession plan under which long-serving Chief Executive Officer Donald Poulton will retire at mid-year.

Vertiv Holdings (NYSE:VRT) has finalized its acquisition of ThermoKey, a specialized European manufacturer of heat-rejection and heat-exchange systems, directly expanding its critical digital infrastructure portfolio.

JinkoSolar Holding (NYSE:JKS) announced that its Board of Directors has declared a standalone cash dividend, accelerating its structural capital return initiatives.

GloBra FZ-LLC has built a blockchain-based ecosystem designed to support online businesses of all kinds.

Its owner and inventor, Dr. Wolfgang Pinegger, has secured patents for the underlying technology in both the European Union and the United States - the two jurisdictions that matter most for a platform with global ambitions.

To understand what those patents actually protect, GLMall put the question to ChatGPT. The resulting assessment is worth reading in full, not least because it declines to overstate the case.

ArrowMark Financial (NASDAQ:BANX) declared its monthly cash distribution for June 2026, sustaining its consistent capital return schedule on the back of resilient quarterly earnings.

Alibaba Group Holding (NYSE:BABA) has submitted a $1.5 billion proposal to acquire Chinese grocery delivery company Pupu, sparking an aggressive bidding war as part of a strategic offensive to capture local digital commerce market share from its primary online services rival, Meituan.

HUTCHMED (NASDAQ:HCM) reported detailed Phase III data for its investigational oral spleen tyrosine kinase (Syk) inhibitor, sovleplenib, at the European Hematology Association (EHA) 2026 Congress.

HF Foods Group (NASDAQ:HFFG) announced that its Board of Directors has adopted a limited-duration stockholder rights plan, commonly known as a "poison pill," intended to protect corporate assets against potential hostile takeover attempts.

AbbVie (NYSE:ABBV) announced long-term follow-up results from its landmark Phase 3 CLL14 clinical trial, reinforcing the durable efficacy of its BCL-2 inhibitor Venclexta (venetoclax) when used as a fixed-duration therapy.

SpaceX (NASDAQ:SPCX) completed its highly anticipated transition to the public markets, staging the largest initial public offering in corporate history.

LIXTE Biotechnology (NASDAQ:LIXT) entered into a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, executing a complete structural transformation away from its legacy clinical-stage oncology pipeline into a dedicated public-market platform for AI and utility energy infrastructure.

GSK (NYSE:GSK) announced that momelotinib, its approved Janus kinase (JAK) inhibitor, has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of VEXAS syndrome.

Oil prices fell more than 2% on Friday, extending a downswing from the previous session after U.S. President Donald Trump canceled plans for targeted military strikes against Iran.

Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).

Canaan (NASDAQ:CAN) announced its unaudited operational updates for May 2026, highlighting significant advancements in energy efficiency and geographic infrastructure expansions.

C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.

Purple Biotech (NASDAQ:PPBT) unveiled new preclinical data for IM1240, its lead T-cell engager candidate utilizing the proprietary CAPTN-3 platform, at the European Association for Cancer Research (EACR) 2026 Congress.

Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.

Vera Bradley (NASDAQ:VRA) reported an unexpected rise in profit margins and its first quarterly top-line expansion in over four years, signaling that its comprehensive brand overhaul is beginning to resonate with retail consumers.

Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.

Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.